oncology. Based on promising early results, clinical applications for cardiac PET have emerged. For the assessment of myocardial viability and perfusion, PET is still widely regarded as the noninvasive gold standard. Comparison with other techniques has refined their application and allowed for improved conventional imaging approaches. Moreover, PET has substantially contributed to a better understanding of various disease processes, for example, in patients with severe coronary artery disease and ischemically compromised but viable myocardium.
A major limitation for the widespread use of PET remains the high cost, reflecting the sophisticated imaging technology and the need of a cyclotron on-site or in close proximity for production of short-lived tracers. However, simplified approaches for positron imaging have been introduced and may -together with an efficient production and distribution of radioisotopes through commercial centers -contribute to a wider clinical application of PET in the future. PET will continue to have its main role as an attractive research tool. Advances in molecular biology and progress in disease-specific therapy have prompted an increasing need for characterization of physiologic and biologic parameters in the heart. New tracer approaches aiming at molecular targets may be suited to monitor specific therapeutically induced changes in cellular function. The uniqueness of this information may contribute to define the clinical future of PET and noninvasive cardiovascular imaging in general. Positron emission tomography (PET) is a high-end imaging technique, which combines superior detection sensitivity with an almost unlimited availability of radiotracers. Shortlived positron emitters such as oxygen-15, nitrogen-13, carbon-, and fluorine-18 represent ideal isotopes for labeling of biomolecules for in vivo characterization of physiologic and biochemical processes. Dynamic data acquisition with high temporal resolution combined with attenuation correction allows for tracer kinetic modeling and calculation of truly quantitative information by noninvasive means.
After its introduction nearly 30 years ago, PET was first established in academic centers for clinical research in neurology, cardiology, and 5
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This chapter highlights the potential of PET for imaging of cardiovascular disease. The methodologic background is outlined first, before major practical applications and biologic imaging targets in the heart are summarized. Finally, an outlook into the future, comprising novel molecular tracers and advanced imaging technology, is given.
Technical Aspects of PET Imaging
Imaging Methodology
Beta-decay of PET radiotracers results in emission of a positron, which immediately annihilates itself together with an electron. Annihilation results in emission of two 511-keV photons traveling in 180° opposite directions. Those photons are detected as coincidences in the crystal ring of the PET scanner, allowing for accurate localization of the origin of decay ( Figure 5 .1). The spatial resolution of currently available PET systems is in the range of 4-8 mm. Another feature of dedicated PET scanners is their high temporal resolution, allowing for dynamic imaging of radiotracer kinetics as a prerequisite for noninvasive absolute quantification of biologic processes. Correction of emission data for tissue photon attenuation is a further prerequisite for tracer quantification. This is easily and readily accomplished by performance of an additional transmission scan with external 511-keV sources, which is used for calculation of regional attenuation coefficients and subsequent correction of emission images.
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Noninvasive Imaging of Myocardial Ischemia
Because dedicated PET scanners are expensive and not widely available, alternative strategies have been developed for imaging the cardiac distribution of PET tracers with conventional gamma cameras. One is single photon emission computed tomography (SPECT) imaging of single 511-keV photons with an ultrahigh energy collimator 1 ; the other is coincidence imaging with a dual-headed gamma camera.
2 These approaches are characterized by lower spatial resolution and detection sensitivity, and do not allow for dynamic imaging and absolute quantification. But, especially for 511-keV SPECT imaging of F-18 fluorodeoxyglucose (FDG) in the assessment of myocardial viability, considerable evidence has accumulated supporting the clinical usefulness of this simplified strategy. 
Radioisotopes and Radiopharmaceuticals
Production of most radioisotopes for labeling of PET radiopharmaceuticals requires a cyclotron. The "medical" cyclotrons used at PET facilities accelerate either protons or deuterons onto a suitable target. Neutrons in the target nuclei are replaced by positively charged particles, resulting in short-lived isotopes that undergo b(+)-decay (Table 5 .1). The most common PET radionuclide, fluorine-18, is, e.g., produced by the 18 O(p, n) 18 F reaction. That means, a target containing oxygen-18 (in the form of 18 Oenriched water) is bombarded with protons, resulting in fluorine-18 by replacement of a neutron with a proton in the nucleus. Alternatively, some isotopes such as the perfusion tracer tion, which aim at imaging of molecular structures such as extracellular matrix, membrane molecules, or intracellular products of gene expression. Those are expected to broaden the spectrum of biologic targets for clinical cardiac PET imaging in the future.
Noninvasive Quantification of Biologic Processes
PET is a truly quantitative imaging tool because it allows measurement of localized radiotracer concentration in the body in absolute units of radioactivity concentration with high accuracy and precision. A necessity for quantification is the routine availability of correction algorithms to eliminate sources of error in raw images. PET imaging implies corrections for random and scattered coincidences, for dead-time loss of detectors, for partial volume effects and resolution recovery, and, most importantly, for tissue attenuation of photons. The resulting images of regional radioactive tracer distribution are usefully applied to answer clinical and scientific questions. Software algorithms are available, which are similar to those applied for SPECT image display, and allow for reangulation of tomographic images along cardiac short and long axes, and for calculation of polar maps.
With the additional use of tracer kinetic modeling, however, there is the potential for substantial improvement of the type and quality of information obtained from biologic data. Kinetic modeling of tracers in the heart requires acquisition of a dynamic imaging sequence, which generates serial images at various time points after radiotracer injection. This allows for extraction of time-activity curves for myocardial segments using software algorithms. The time course of tracer concentration in arterial blood (arterial input function) is additionally obtained using a region of interest in the left ventricular cavity or left atrium. Time-activity curves are subsequently fitted to suitable compartmental models, which characterize the tissue kinetics of the respective tracers. For O-15 water as a freely diffusible perfusion tracer, e.g., this is a simple single-compartment model with one extravascular compartment. 4 For the perfusion tracer N-13 ammonia, which is taken up by tissue and subsequently used for glutamine synthesis, a two-compartment model with an extravascular rubidium-82 are obtained from specific generators containing longer-lived parent nuclides.
Positron-emitting isotopes of the major bioelements nitrogen, oxygen, and carbon are available, along with fluorine-18, for labeling of various biocompounds. Radiopharmaceuticals that have been applied for cardiac imaging in the clinical setting are summarized in Table 5 .2. At present, these tracers target myocardial perfusion, metabolism, innervation, and receptors. Further tracers are under experimental evalua- and a metabolic compartment can be applied. 5 Kinetics of the metabolic tracer F-18 FDG can be described by a three-compartment model. 6 FDG is taken up by myocardium via specific membrane glucose transporters. Intracellularly, FDG is phosphorylated by hexokinase to FDG-6-phosphate. FDG-6-phosphate is not a good substrate for further metabolism and is thus trapped intracellularly. Compartmental modeling of tracer kinetics yields rate constants that quantitatively reflect biologic processes ( 
PET Imaging of Cardiac Physiology and Biology
Myocardial Blood Flow
Myocardial perfusion PET imaging is accomplished using flow tracers at rest and during pharmacologic stress. 7, 8 Dipyridamole or adeno-sine are applied for pharmacologic vasodilation at doses frequently used for SPECT imaging. Physical exercise is not well accepted for stress flow measurements with PET because of the high likelihood of patient motion during imaging in the ring scanner. Relative regional perfusion abnormalities are assessed from static images using N-13 ammonia and Rb-82 ( In a clinical setting, the purpose of qualitative PET perfusion imaging is similar to that of SPECT, namely, to detect myocardial ischemia and/or infarction in patients with suspected or known coronary artery disease, to determine extent and severity of the disease, to determine individual risk for cardiac events, and to thereby guide further workup. [9] [10] [11] The diagnostic accuracy for detection of coronary artery disease is Shown are the major steps of quantification of myocardial blood flow using N-13 ammonia, as applied at the TU München. Left, Myocardial segments and blood pool are identified using software-based volumetric sampling. Time-activity curves are extracted from the dynamic imaging dataset for these segments. Middle, Individual time-activity curves are fitted to a validated threecompartment model for ammonia (white stars -measured activity over time in representative myocardial segment; white line -fitted myocardial time activity curve; red line -blood pool curve). Right, After the fitting procedure, the influx constant K1, which reflects absolute myocardial blood flow, is depicted for all myocardial segments as two-or three-dimensional polar map.
dependent and -independent vasodilation, PET serves increasingly as an endpoint to measure effects of risk factor manipulation, new drugs, and other therapeutic approaches in the prevention of clinical coronary artery disease.
Myocardial Viability
Clinical Importance
PET has not only had a fundamental role in the clinical emergence of noninvasive viability imaging. Regarded as an imaging "gold standard," it has contributed to validation and refinement of other imaging approaches. The largest cumulative experience on the impact of viability imaging on patient management is derived from metabolic studies using F-18 FDG. The quantitative nature of PET has also provided significant information for a better understanding of the pathophysiologic interrelations among myocardial blood flow, metabolism, and contractile function involved in development of severely jeopardized myocardium.
higher compared with SPECT, 12 which can be explained by higher spatial resolution, higher extraction fraction of PET flow tracers, and absence of attenuation artifacts. Incremental prognostic value of qualitative perfusion PET over clinical variables for prediction of cardiac events has been demonstrated. 13 Additionally, it has been shown that the more expensive PET perfusion imaging approach can still be costeffective in a specific setting compared with other strategies, including exercise electrocardiogram and SPECT. 14 The major impact of PET perfusion studies is derived from the potential for noninvasive quantification of myocardial blood flow as explained above, allowing for studies of coronary microcirculatory regulation on the resistance level. Although potentially helpful in the clinical diagnosis of coronary artery disease, 15 absolute flow measurements by PET have mainly been applied in studies to understand the effects of risk factors of coronary artery disease, such as hyperlipidemia, diabetes, and smoking, leading to an increased emphasis on preventive therapy. [16] [17] [18] [19] [20] [21] With the ability to test specific components of microvascular function such as endothelial- F-18 FDG myocardial imaging is the most frequent clinical application of cardiac PET. 7, 8 For assessment of myocardial viability, F-18 FDG is combined with resting perfusion measurements using either a second PET tracer in the same session, or (if performed at a place remote from a cyclotron and not equipped with a perfusion tracer generator) in combination with perfusion SPECT. PET viability imaging is obtained in patients with dysfunctional, hypoperfused myocardial regions to determine the likelihood of a benefit from revascularization. Residual metabolic activity is an indicator of myocardial viability, and thus of reversibility of contractile dysfunction. Regional reduction of FDG uptake in proportion to perfusion (perfusion/metabolism match) reflects scar and thus irreversibility of contractile dysfunction (Figure 5.4 ; see color section), whereas increased regional FDG uptake relative to myocardial perfusion (perfusion/ metabolism mismatch) indicates ischemically compromised but viable myocardium (Figure 5.5; see color section).
Since introduction of the approach in 1986, 22 it has been shown in a variety of studies that recovery of function after revascularization can be predicted by PET with high sensitivity of 85%-90% and specificity of 75%-85%. 23 Additionally, the importance of identification of viable myocardium has increasingly been investigated beyond the prediction of functional recovery, which is only a surrogate endpoint for clinical and prognostic importance. It has, e.g., been shown that recovery of function is coupled with improvement of heart failure symptoms. 24 Moreover, patients benefit through reduced periand postoperative risk when PET criteria are used for selection for bypass surgery as compared with those selected without a PET study. 25 An increased preoperative mortality and limited functional recovery were observed when revascularization was delayed after detection of viable myocardium by PET, suggesting that the hibernating state is unstable and requires immediate attention. 26 PET viability studies have a significant impact on clinical decision making in patients with coronary disease and left ventricular (LV) dysfunction. 27 Finally, randomized trials based on PET are currently underway to further establish the clinical importance of viability imaging as an evidence-based approach. disease. 29, 33 Abnormal glucose handling or even type 2 diabetes that frequently have remained undetected account for the poor image quality in many of these patients.
• Euglycemic hyperinsulinemic clamping is an approach that mimics the postabsorptive steady-state, 29, 34 and has become an alternative to oral glucose loading for enhancing glucose utilization. 29 Insulin clamping stimulates uptake of glucose and FDG in the myocardium and in skeletal muscle and yields images of consistently high diagnostic quality, even in patients with diabetes.
• Several studies 30, [35] [36] [37] have demonstrated that oral administration of a nicotinic acid or its derivatives is another effective technique to improve FDG image quality. When combined with small amounts of short-acting insulin, good image quality can be obtained also in diabetic subjects. 35 Nicotinic acid inhibits peripheral lipolysis and thus reduces plasma FFA concentrations. Acipimox is a nicotinic acid derivative that is 20 times more potent and has more favorable kinetics than nicotinic acid. 38 Importantly, with the exception of flushing, no side effects of Acipimox have been observed.
Metabolic Standardization
Diagnostic quality of myocardial FDG images is influenced by the concentration of tracer in myocardium and blood. Myocardial FDG uptake depends on glucose and insulin plasma concentrations as well as the rate of glucose utilization. High glucose plasma concentrations degrade the quality of the myocardial FDG uptake image. [28] [29] [30] Myocardial glucose uptake also depends on cardiac work, plasma levels of Free Fatty Acids (FFA) and other substrates, insulin, catecholamines, and oxygen supply. 31 Standardization of the metabolic environment is necessary for clinical myocardial FDG imaging. 32 There are several accepted methods for improvement of myocardial FDG PET image quality:
• Oral glucose loading is often used to stimulate insulin secretion and myocardial glucose utilization. It enhances the image quality with more homogeneously distributed FDG uptake than observed during the fasting state. The preparation of patients for PET studies and detailed protocols for metabolic and perfusion imaging have been described in procedural guidelines by professional societies. 7, 8 
Other Imaging Targets
Substrate Metabolism
In addition to F-18 FDG, a variety of tracers exists to study quantitatively the complex interaction between substrate delivery, uptake, and turnover in myocardial tissue under various physiologic and pathophysiologic conditions. The myocardial metabolic rate of glucose is quantified from dynamic FDG PET, 6 or, as shown more recently, using C-11 glucose. 39 Additionally, use of fatty acids as the second major substrate can be examined using C-11 palmitate 40 or F-18 fluoro-6-thia-heptadecanoic acid (FTHA). 41 C-11 acetate is another metabolic tracer that is extracted proportionally to myocardial blood flow, then rapidly enters the tricarboxylic acid cycle and is metabolized to carbon dioxide. Washout of C-11 from the myocardium is used to quantify turnover in the tricarboxylic acid (TCA) cycle as the final common pathway of all substrates, and thus to measure overall oxidative metabolism. 42, 43 When combined with measures of cardiac contractile performance, C-11 acetate PET can be used for a noninvasive estimation of cardiac efficiency (defined as the relation between work and oxygen consumption). 44 This approach is of special interest in heart failure, 45 where it can be used to measure effects of drugs such as beta-blockers or dobutamine, 44, 46 and thereby to optimize medical therapy.
Autonomic Innervation
The autonomic nervous system has a central role for regulation of cardiac performance under various physiologic and pathophysiologic conditions. The importance of alterations of autonomic innervation in the pathophysiology of heart disease has been increasingly emphasized. Using radiolabeled catecholamine analogs such as C-11 hydroxyephedrine (HED) or F-18 fluorodopamine, PET provides noninvasive information about global and regional myocardial sympathetic innervation. It has substantially facilitated and refined the study of the heart's nervous system in health and disease, and has significantly contributed to a continuous improvement of the understanding of cardiac pathophysiology.
In transplanted hearts, which are completely denervated early after surgery, partial sympathetic reinnervation has been identified (Figure 5.6; see color section). 47 The reinnervated heart research are often significantly overlapping and may benefit from each other:
• The regulation of blood vessel growth is one area of interest for both oncologists and cardiologists. a v b 3 integrins are expressed on the endothelial surface during tumor angiogenesis and metastasis growth, and can be identified in the experimental setting using F-18-labeled RGD peptides. 63 These proteins are also a target for cardiac molecular imaging, when expressed during angio-/ vasculogenesis, during rapid development of coronary stenosis, e.g., restenosis after interventions, or during migration of inflammatory cells.
• Apoptosis (programmed cell death) is a therapeutic target in tumor treatment, but is also known to have a pivotal role in cardiovascular disease, e.g., in transplant rejection and plaque destabilization. 64 Recently, annexin-V, a molecule that specifically binds to phosphatidylserine, which is expressed on the surface of cells entering the apoptotic cascade, has been successfully labeled with fluorine-18 and is now available for PET. 65 Previously, this tracer was available only as technetium-99 m-labeled compound for conventional scintigraphy.
• Within recent years, reporter gene imaging has emerged as an innovative strategy for noninvasive visualization of genetic processes. 66 The principle of reporter gene imaging is based on vector-mediated overexpression of a transgene in host tissue which encodes for an enzyme, a receptor, or a transport protein that is normally not present in the target area. Suitable reporter probes are labeled substrates or ligands for the reporter gene product. PET can be applied to detect accumulation of the probe, which specifically identifies the reporter gene product. 67 The imaging signal thus indirectly reflects expression and transcriptional regulation of the reporter gene. An example is the use of the herpesviral thymidine kinase reporter gene and radiolabeled nucleosides as reporter probes (Figure 5.7 ; see color section). This technique will allow for monitoring the success of gene therapy, when reporter genes are combined and coexpressed with therapeutic genes. It may also allow for monitoring of endogenous gene expression, if reporter genes are expressed under control of specific promoters that are sensitive to endogenous gene products. 68 Or the reporter was used as a model for determination of physiologic effects of innervation by intraindividual comparison of denervated and reinnervated myocardium, substantiating the role of innervation for regulation of myocardial blood flow, metabolism, and contractility. [48] [49] [50] Furthermore, alterations of cardiac innervation were identified in diabetes mellitus, ischemic syndromes, 51 arrhythmogenic diseases, 52, 53 and heart failure, 54, 55 and their pathophysiologic relevance 56 as well as prognostic implications 57 were identified in subsets of patients.
Receptors
Various myocardial receptors have been identified to have a role in cardiovascular pathophysiology, and thus represent attractive targets for imaging. The nonselective b-adrenergic receptor ligand C-11 CGP12177 has been applied to visualize down-regulation of b-receptors in heart failure, 58 and to identify pre-/postsynaptic imbalance in cardiomyopathy and arrhythmogenic diseases. 52, 59 Other adrenergic receptor ligands have been introduced, but not yet applied in humans. 60, 61 Furthermore, C-11 MQNB, a muscarinic receptor agonist, has been applied to describe up-regulation of myocardial muscarinic receptors in heart failure as a potential adaptive mechanism. 62 Further attractive targets for myocardial receptor imaging comprise, e.g., the opiate, endothelin, angiotensin, and adenosine receptor systems. But issues related to low selectivity and affinity, high nonspecific binding, lack of hydrophilicity (to avoid binding to internalized inactive receptors), and pharmacologic/toxicologic effects along with complicated, less reliable tracer synthesis have precluded a more widespread application of available receptor ligands for cardiac PET, and will need to be overcome in the future.
Further Molecular Probes
The recent advent and rapid success of molecular imaging has resulted in a series of very promising novel tracer approaches that go beyond identification of flow, metabolism, and innervation, and target further specific biomechanisms involved in disease. It has also become obvious that developments in oncologic and cardiologic gene can be expressed in stem cells before their transplantation for subsequent in vivo monitoring of the fate of these therapeutic cells. 69 For all of these new molecular PET assays, the amount of signal produced, target-to-background ratios, morphologic localization, and specific probe activity are critical issues that need to be overcome for clinical application and will pose a continuous challenge for further developments in camera technology.
Hybrid PET/Computed Tomography Imaging
Driven by technical developments and clinical diagnostic needs in oncology, the newest generation of PET scanners is now available in combination with X-ray computed tomography (CT). These hybrid PET/CT scanners incorporate functional/biologic information from PET and morphologic information from CT into a single examination, and have been demonstrated to provide superior diagnostic accuracy for tumor staging. 70, 71 The latest generation of PET/CT scanners is equipped with ultrafast multislice CT, opening grounds for cardiac PET/CT imaging (Figure 5.8; see color section). These scanners hold great promise for a "one-stop shop" biologic/morphologic evaluation of the heart. In the future, functional PET assessment of tissue blood flow and viability will be combined with noninvasive CT assessment of coronary arteries, calcifications, and ventricular function. Furthermore, localization of highly specific molecular signals from myocardium or coronary plaques determined by PET may be facilitated through additional structural information from CT imaging.
Some technical challenges do exist for quantitative cardiac PET/CT. Because CT is acquired during breathhold, misalignment with PET data, which reflect an average over the breathing cycle, can occur. Misalignment adversely influences attenuation correction, quantification, and morphologic localization of PET tracer uptake. and for measurement of myocardial blood flow. It will continue to serve as an endpoint for evaluation of medical and interventional therapeutic approaches. High costs will remain a limitation for its use as a standard procedure, but new developments in technology may allow for a more cost-effective, widespread use of positron-emitting tracers and for integrated biologic/morphologic imaging.
The major impact of PET will continue to be derived from its application as a powerful research tool. Availability of micro PET systems for small animal imaging facilitates the evaluation of novel molecular probes and their translation to human application. 73 Combination of PET with morphologic imaging strategies will then allow for in vivo characterization and localization of molecular mechanisms in the human heart in health and disease. Thereby, PET will remain a forerunner for the future development of the entire field of cardiovascular imaging.
Studies addressing this issue, e.g., by respiratory gating, 72 are currently underway and will provide the methodologic background for future trials evaluating the clinical benefit of PET/CT imaging in patients with cardiac disease.
Summary and Future Perspectives
The application of PET as a research tool has substantially improved understanding of pathophysiologic processes in the heart. Clinical applications for assessment of myocardial viability and perfusion have emerged in the past. Knowledge derived from cardiac PET imaging has been successfully transferred to other imaging techniques, leading to refinement of their application and to increased acceptance of noninvasive cardiac imaging in general.
Clinically, PET is still regarded as the gold standard for detection of myocardial viability 
